Mesa Laboratories (MLAB) Given Daily Coverage Optimism Score of 0.13
Media stories about Mesa Laboratories (NASDAQ:MLAB) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Mesa Laboratories earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 45.1121237635549 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
A number of equities analysts recently weighed in on the company. Zacks Investment Research lowered Mesa Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, June 10th. BidaskClub lowered Mesa Laboratories from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Finally, TheStreet lowered Mesa Laboratories from a “b” rating to a “c+” rating in a research report on Monday, July 31st.
Shares of Mesa Laboratories (NASDAQ MLAB) traded down 0.62% during midday trading on Friday, reaching $129.52. The company’s stock had a trading volume of 1,031 shares. The stock has a 50-day moving average of $141.10 and a 200 day moving average of $136.66. Mesa Laboratories has a 12 month low of $103.51 and a 12 month high of $169.80. The company has a market cap of $486.74 million, a price-to-earnings ratio of 46.56 and a beta of 0.46.
Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings data on Monday, July 31st. The medical instruments supplier reported $0.39 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.56 by $0.17. Mesa Laboratories had a return on equity of 16.58% and a net margin of 11.31%. The business had revenue of $22.67 million during the quarter, compared to the consensus estimate of $22.90 million. On average, analysts predict that Mesa Laboratories will post $2.72 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Thursday, August 31st will be given a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.49%. The ex-dividend date is Tuesday, August 29th. Mesa Laboratories’s dividend payout ratio (DPR) is presently 22.94%.
In other news, insider Glenn E. Adriance sold 4,000 shares of Mesa Laboratories stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $148.98, for a total value of $595,920.00. Following the completion of the transaction, the insider now directly owns 10,000 shares of the company’s stock, valued at approximately $1,489,800. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director H Stuart Campbell sold 608 shares of Mesa Laboratories stock in a transaction dated Friday, August 11th. The stock was sold at an average price of $134.08, for a total value of $81,520.64. Following the completion of the transaction, the director now directly owns 45,368 shares of the company’s stock, valued at $6,082,941.44. The disclosure for this sale can be found here. Over the last three months, insiders sold 24,760 shares of company stock valued at $3,469,708. Corporate insiders own 17.00% of the company’s stock.
About Mesa Laboratories
Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.
Receive News & Stock Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related stocks with our FREE daily email newsletter.